Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

Bhatt, Deepak L., Hirsch, Alan T., Ringleb, Peter A., Hacke, Werner, Topol, Eric J. and On behalf of the CAPRIE investigators (2000) Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. American Heart Journal, 140 1: 67-73. doi:10.1067/mhj.2000.108239


Author Bhatt, Deepak L.
Hirsch, Alan T.
Ringleb, Peter A.
Hacke, Werner
Topol, Eric J.
On behalf of the CAPRIE investigators
Title Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin
Journal name American Heart Journal   Check publisher's open access policy
ISSN 0002-8703
1097-6744
Publication date 2000-07
Sub-type Article (original research)
DOI 10.1067/mhj.2000.108239
Volume 140
Issue 1
Start page 67
End page 73
Total pages 7
Place of publication Philadelphia, PA, United States
Publisher Mosby
Language eng
Formatted abstract
Background:
Repeat hospitalizations of patients with atherosclerosis represent a considerable burden on the health care system. We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding.

Methods and Results:
The Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial was a randomized, blinded, multicenter, trial of 19,185 patients with atherosclerotic disease manifested as recent ischemic stroke or myocardial infarction or symptomatic peripheral arterial disease. Without any double- counting of events, the number of rehospitalizations for ischemic events (defined as angina, transient ischemic attack, or limb ischemia) or bleeding events was determined for the entire cohort. There was a significant reduction in the total number of rehospitalizations for ischemic events or bleeding with clopidogrel use compared with aspirin (1502 vs 1673; P = .010) over an average of 1.6 years of treatment. This reduction in rehospitalization was consistent across individual outcomes of angina, transient ischemic attack, limb ischemia, and bleeding. Compared with aspirin, clopidogrel also resulted in a 7.9% relative risk reduction in a combined end point of vascular death, stroke, myocardial infarction; or rehospitalization for ischemic events or bleeding (15.1% to 13.7% at 1 year; P = .011). Adjusting for baseline prognostic variables, clopidogrel therapy was an independent predictor for reduction of vascular death, stroke, myocardial infarction, or rehospitalization for ischemic events or bleeding (P = .009).

Conclusions:
Treatment with clopidogrel results in a significant decrease in the need for rehospitalization for ischemic events or bleeding compared with aspirin. This meaningful end point tracks well with other, more traditional measures of outcome and has incremental value beyond such end points.
Keyword Congestive heart failure
Wave myocardial infarction
Acute coronary syndromes
Unstable angina
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 77 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 97 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 07 Dec 2010, 09:58:30 EST